Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18611087 | HUMAN PD-L2 ANTIBODIES AND METHODS OF USE THEREFOR | March 2024 | May 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18595279 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18595275 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | March 2024 | December 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18383043 | ANTI-CEACAM6 ANTIBODIES AND METHODS OF USE | October 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18481547 | METHODS OF USING RARy AGONISTS FOR CANCER TREATMENT | October 2023 | June 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18227828 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | July 2023 | April 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18216085 | Anti-Axl Antagonistic Antibodies | June 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18255880 | B7-H3 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | June 2023 | December 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18256045 | TROP2 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREFOR | June 2023 | December 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18191372 | Method And Molecules | March 2023 | March 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18173413 | LINKERS FOR ANTIBODY DRUG CONJUGATES | February 2023 | May 2024 | Allow | 14 | 1 | 0 | No | No |
| 18172123 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | February 2023 | June 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18164519 | ANTI-CCR7 ANTIBODY DRUG CONJUGATES | February 2023 | July 2024 | Allow | 18 | 1 | 0 | No | No |
| 18161423 | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | January 2023 | March 2024 | Allow | 13 | 1 | 0 | No | No |
| 18145811 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACROLIDE DIASTEREOMERS, METHODS OF THEIR SYNTHESIS AND THERAPEUTIC USES | December 2022 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18062355 | ANTI-MERTK AGONISTIC ANTIBODIES AND USES THEREOF | December 2022 | July 2024 | Allow | 20 | 1 | 0 | No | No |
| 17993528 | METHODS OF USING RARy AGONISTS FOR CANCER TREATMENT | November 2022 | June 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17986430 | COMBINATION TAXOID NANOEMULSION WITH IMMUNOTHERAPY IN CANCER | November 2022 | September 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17823117 | IMMUNOGENIC COMPOUNDS FOR CANCER THERAPY | August 2022 | October 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17820179 | COMBINATION THERAPY USING C-C CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS | August 2022 | February 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 17817100 | HUMANIZED ANTIBODY AGAINST O-ACETYLATED GD2 GANGLIOSIDE (OACGD2) | August 2022 | September 2024 | Abandon | 26 | 3 | 0 | Yes | No |
| 17851618 | NaPi2B-TARGETED POLYMER ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | June 2022 | November 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17838016 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | June 2022 | September 2023 | Allow | 16 | 1 | 0 | No | No |
| 17744134 | METHODS AND MATERIALS FOR TREATING CYTOKINE RELEASE SYNDROME | May 2022 | October 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17560232 | ANTI-CEACAM6 ANTIBODIES AND METHODS OF USE | December 2021 | July 2023 | Allow | 19 | 1 | 0 | No | No |
| 17516916 | Anti-Axl Antagonistic Antibodies | November 2021 | March 2023 | Allow | 17 | 1 | 0 | No | No |
| 17598280 | Antibodies to Pyroglutamate Amyloid-B and Uses Thereof | September 2021 | February 2025 | Allow | 40 | 1 | 0 | No | No |
| 17425006 | COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING TUMOR | July 2021 | May 2025 | Allow | 46 | 1 | 0 | No | No |
| 17424889 | NOVEL ANTI-CD40 ANTIBODIES | July 2021 | August 2024 | Allow | 36 | 1 | 0 | No | No |
| 17423775 | VARIANTS OF ERYTHROFERRONE AND THEIR USE | July 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17366837 | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | July 2021 | January 2023 | Allow | 19 | 1 | 0 | No | No |
| 17358703 | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | June 2021 | August 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17348236 | COMPOUNDS AND CONJUGATES THEREOF | June 2021 | July 2022 | Allow | 13 | 2 | 1 | Yes | No |
| 17413152 | ANTI-IL-17A ANTIBODY AND USE THEREOF | June 2021 | September 2024 | Allow | 40 | 1 | 0 | No | No |
| 17339549 | ANTI-BCMA ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | June 2021 | March 2024 | Allow | 33 | 1 | 1 | No | No |
| 17281062 | ANTI-B7H3 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICINAL USE THEREOF | March 2021 | March 2025 | Allow | 47 | 2 | 0 | No | No |
| 17276706 | DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES | March 2021 | March 2024 | Allow | 36 | 0 | 0 | No | No |
| 17276686 | ANTI-TNFR2 ANTIBODIES AND USES THEREOF | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17275030 | EPITOPES | March 2021 | May 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17193631 | COMBINATION THERAPY COMPRISING AXL/MER AND PD-1/PD-L1 INHIBITORS | March 2021 | September 2024 | Allow | 43 | 3 | 0 | No | No |
| 17189918 | Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers | March 2021 | November 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17272241 | Anti-CD3 Antibody Folate Bioconjugates and Their Uses | February 2021 | April 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17185012 | CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | February 2021 | December 2023 | Allow | 34 | 1 | 1 | No | No |
| 17264721 | Linkers and conjugates | January 2021 | April 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17263322 | PROTEIN RECOGNIZING DRUG MOIETY OF ANTIBODY-DRUG CONJUGATE | January 2021 | March 2025 | Allow | 49 | 1 | 1 | No | No |
| 17262917 | OFF-THE-SHELF CANCER VACCINES | January 2021 | April 2025 | Allow | 50 | 1 | 1 | No | No |
| 17156401 | COMPOSITIONS, METHODS AND USES FOR MODULATING THE TUMOR MICROENVIRONMENT TO ENHANCE ANTITUMOR IMMUNITY | January 2021 | January 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17154350 | HUMAN ANTI-IFN-ALPHA ANTIBODIES | January 2021 | November 2023 | Allow | 34 | 0 | 0 | No | No |
| 17258348 | BISPECIFIC ANTIBODIES TARGETING IMMUNE CHECKPOINTS | January 2021 | December 2023 | Allow | 35 | 1 | 0 | No | No |
| 17059019 | ANTIBODY BINDING TO AXL PROTEIN AND APPLICATION THEREOF | November 2020 | February 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17058472 | PYRROLOBENZODIAZEPINE CONJUGATES | November 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17055499 | AXL-TARGETING ANTIBODY, ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | November 2020 | November 2023 | Allow | 36 | 1 | 0 | No | No |
| 17042872 | SELECTIVE REDUCTION OF ANTIBODIES | September 2020 | March 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17040269 | HUMAN PD-L2 ANTIBODIES AND METHODS OF USE THEREFOR | September 2020 | December 2023 | Allow | 39 | 1 | 0 | No | No |
| 16978991 | RELEASABLE ANTIBODY CONJUGATES | September 2020 | August 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17011542 | METHOD OF PRODUCING IMMUNOTHERAPY VACCINE | September 2020 | February 2023 | Allow | 30 | 1 | 0 | No | No |
| 16996949 | THERAPEUTIC ANTIBODY AND USES THEREOF | August 2020 | August 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16971219 | ANTIBODY-DRUG CONJUGATE HAVING ACIDIC SELF-STABILIZATION JUNCTION | August 2020 | June 2025 | Allow | 58 | 2 | 1 | Yes | No |
| 16993539 | Formulations of Benzazepine Conjugates and Uses Thereof | August 2020 | April 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16966072 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | July 2020 | September 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16963380 | ARGINASE SUPPRESSION FOR CANCER TREATMENT | July 2020 | October 2024 | Abandon | 50 | 3 | 1 | No | No |
| 16933349 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | July 2020 | February 2024 | Abandon | 43 | 1 | 0 | No | No |
| 16768036 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD2+ CELLS | May 2020 | October 2023 | Abandon | 41 | 0 | 1 | No | No |
| 16765486 | MULTISPECIFIC ANTIGEN BINDING PROTEINS | May 2020 | February 2024 | Abandon | 44 | 1 | 1 | No | No |
| 16763705 | METHODS AND COMPOSITIONS FOR TARGETING DEVELOPMENTAL AND ONCOGENIC PROGRAMS IN H3K27M GLIOMAS | May 2020 | May 2024 | Allow | 49 | 4 | 1 | Yes | No |
| 16763185 | HUMANIZED ANTIBODIES TARGETING HUMAN TISSUE FACTOR | May 2020 | March 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16760910 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | May 2020 | March 2024 | Allow | 47 | 3 | 1 | Yes | No |
| 16862358 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD123 IMMUNOCONJUGATES | April 2020 | April 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16860822 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | April 2020 | May 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 16856689 | CONJUGATES AND METHODS OF USE THEREOF FOR SELECTIVE DELIVERY OF IMMUNE-MODULATORY AGENTS | April 2020 | February 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16852371 | METHODS OF TREATING RENAL CANCER WITH AN ANTI- PSMA/CD3 ANTIBODY | April 2020 | May 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16650429 | COMPOUNDS, REAGENTS, AND USES THEREOF | March 2020 | January 2023 | Allow | 34 | 1 | 0 | No | No |
| 16647711 | IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER | March 2020 | December 2024 | Allow | 57 | 3 | 1 | No | No |
| 16645315 | ANTITUMOR AGENT AND ANTITUMOR EFFECT POTENTIATOR | March 2020 | July 2024 | Allow | 53 | 5 | 0 | Yes | Yes |
| 16644751 | HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY | March 2020 | June 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16643756 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER | March 2020 | August 2022 | Abandon | 29 | 1 | 0 | No | No |
| 16794069 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | February 2020 | September 2023 | Abandon | 43 | 3 | 0 | Yes | Yes |
| 16794056 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | February 2020 | February 2024 | Abandon | 48 | 5 | 0 | Yes | No |
| 16639667 | PYRROLOBENZODIAZEPINE CONJUGATES | February 2020 | December 2022 | Allow | 34 | 1 | 0 | No | No |
| 16780711 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | February 2020 | November 2022 | Allow | 33 | 1 | 1 | Yes | No |
| 16626456 | ANTI-MERTK AGONISTIC ANTIBODIES AND USES THEREOF | December 2019 | September 2022 | Allow | 32 | 1 | 1 | No | No |
| 16711652 | COMPOUNDS AND COMPOSITIONS FOR TREATING EGFR EXPRESSING TUMORS | December 2019 | February 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16619846 | Engineered Antibody Compounds and Conjugates Thereof | December 2019 | April 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16616148 | LINKERS FOR ANTIBODY DRUG CONJUGATES | November 2019 | November 2022 | Allow | 36 | 1 | 1 | No | No |
| 16691437 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | November 2019 | December 2023 | Abandon | 49 | 2 | 1 | Yes | No |
| 16615582 | METHOD AND MOLECULES | November 2019 | October 2022 | Allow | 35 | 2 | 0 | Yes | No |
| 16604700 | Immunoconjugate Synthesis Method | October 2019 | January 2023 | Abandon | 39 | 2 | 0 | No | No |
| 16496286 | TREATMENT OF CANCER WITH A SEMAPHORIN-4D ANTIBODY IN COMBINATION WITH AN EPIGENETIC MODULATING AGENT | September 2019 | October 2022 | Allow | 37 | 2 | 0 | Yes | No |
| 16570834 | PROTEIN NANOPARTICLES AND COMBINATION THERAPY FOR CANCER IMMUNOTHERAPY | September 2019 | January 2023 | Abandon | 40 | 3 | 0 | No | No |
| 16490892 | USE OF MTOR INHIBITOR AND CHLOROQUINE FOR TREATING CANCER | September 2019 | December 2021 | Allow | 27 | 1 | 0 | Yes | No |
| 16553339 | COMBINATION THERAPY USING C-C CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS | August 2019 | May 2022 | Allow | 33 | 1 | 1 | No | No |
| 16488459 | IMMUNOCYTOKINE COMBINATION THERAPY | August 2019 | June 2023 | Abandon | 45 | 2 | 0 | No | No |
| 16548215 | METHODS AND MATERIALS FOR TREATING CYTOKINE RELEASE SYNDROME | August 2019 | February 2022 | Allow | 30 | 2 | 0 | No | No |
| 16542642 | NaPi2B-TARGETED POLYMER ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | August 2019 | March 2022 | Allow | 31 | 1 | 0 | Yes | No |
| 16485100 | ANTIBODIES TO TIP1 AND METHODS OF USE THEREOF | August 2019 | February 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16529457 | 2H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | August 2019 | March 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16482173 | ANTI-CCR7 ANTIBODY DRUG CONJUGATES | July 2019 | October 2022 | Allow | 39 | 1 | 1 | Yes | No |
| 16480557 | COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS | July 2019 | November 2021 | Allow | 28 | 1 | 1 | No | No |
| 16513194 | METHODS OF SENSITIZING CANCER CELLS TO IMMUNE CELL KILLING | July 2019 | January 2024 | Abandon | 54 | 6 | 0 | Yes | No |
| 16471395 | ANTI-LILRB3 ANTIBODIES AND METHODS OF USE THEREOF | June 2019 | June 2023 | Allow | 48 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VAN DRUFF, SYDNEY.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VAN DRUFF, SYDNEY works in Art Unit 1643 and has examined 119 patent applications in our dataset. With an allowance rate of 63.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner VAN DRUFF, SYDNEY's allowance rate of 63.9% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by VAN DRUFF, SYDNEY receive 1.60 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by VAN DRUFF, SYDNEY is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +31.1% benefit to allowance rate for applications examined by VAN DRUFF, SYDNEY. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 28.7% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 27.3% of cases where such amendments are filed. This entry rate is in the 29% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 92.9% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.